Generally, biologics are going to be a better fit for a virtual model than small molecules.
The chemistry of drug development requires very specialized expertise, and large pharma/biotech has institutional knowledge that is extremely difficult to compete with. Also, because small molecules can be made of anything, their off-target effects can be difficult to predict (even aspirin is not completely understood).
Nucleotide-based technologies like RNAi ( Alnylam), mRNA ( Moderna), and CRISPR/Cas9 ( Caribou, Editas) would be ideal. Since they are nucleotide-based, binding relies on sequence identity, so it's much closer to a digital system. Theoretically, you can change targets simply by changing the nucleotide sequence, which makes the process much more predictable. Nucleotide binding is generally easier to predict because a 1D search space (the human genome, plus perhaps commensal bacterial genomes) is so much more constrained than a 3D search space (all structures/epitopes present in and on cells). Of course, these technologies have their own issues in that they are new and untested.
Protein-based biologics are arguably a good compromise. For example: enzymes ( enzyme replacement therapy is worth billions of dollars a year), antibodies (seven of the eight top selling drugs in 2013 were antibodies), BiTEs and CAR-Ts (cancer immunotherapy companies like Juno are showing extremely promising results). These technologies provide a more consistent design template than a small molecule (i.e., DNA), but there is still a lot that remains unpredictable, such as off-target binding for antibodies, or even how the protein will fold.
CHOOSE YOUR ADVANTAGE
Without the resources of a large biotech, how can a virtual company compete? After all, pharma/biotech has thousands of potential therapies sitting on the shelf. A therapy that works great in yeast, or even mouse, is not necessarily worth much because most of the risk in drug development happens after the preclinical research stage (an orphan disease with no treatments is an easier sell).
Since the eventual goal is a safe and effective therapy, that means there are three advantages your therapy could have:
More Safety The therapy has already been shown to be safe in a clinical trial, or is a generic/offpatent drug (twoXAR, Recursion, NuMedii) More Efficacy The therapy works in multiple distinct organisms, so it should work in humans (Perlstein lab) More Safety and More Efficacy The therapy comes directly from a human, therefore there is some indication that it's safe and effective in a human (X01, Neurimmune). Recent applications of human genetics in drug discovery (e.g., PCSK9 inhibitors) rely on asimilar concept. 
CREATE AND TEST YOUR THERAPY

